Solventum (NYSE:SOLV) announced today that it completed its previously announced acquisition of Acera Surgical.
Last month, the 3M Health Care spinoff announced an agreement to buy the developer of soft tissue repair treatments for up to $900 million. The deal includes a $725 million cash payment, plus up to $125 million in contingent cash payments based on future milestones.
Acera Surgical develops innovative synthetic options for soft tissue repair using a proprietary electrospinning technology platform. The company’s Restrata products treat hard-to-heal, complex wounds in acute care settings. It currently offers Restrata in the U.S.
Solventum said that Acera’s innovation engine and commercial footprint align with its leadership in advanced wound care. It expects to use its relationships and go-to-market capabilities to accelerate the adoption of Restrata products in the acute care market. Solventum also hopes generate synergies by leveraging its own global footprint.
The company expects to utilize its specialized wound care sales force and leadership in negative pressure wound therapy to support Restrata.
Solventum expects Acera to generate approximately $90 million in sales in 2025. It anticipates a slightly dilutive impact on adjusted earnings per share (EPS) in 2026, then an accretive one in 2027. The company plans to use cash on hand to finance the deal, which it expects to close in the first half of 2026.
“Announcing and completing our first strategic acquisition is a significant milestone and the successful completion of another commitment made as part of our three-phased transformation plan,” said Bryan Hanson, CEO of Solventum. “The addition of Acera’s innovative synthetic tissue matrix technology complements our existing advanced wound care portfolio, enhancing the solutions our specialized commercial team can provide to clinicians and decision makers in acute care settings. We are excited to welcome the Acera team to the Solventum family and look forward to our work together to accelerate growth and create significant value for patients, clinicians and shareholders.”
